Maraviroc--new HIV drug. Emerging options need to be used wisely.
作者信息
Vázquez Enid
出版信息
Posit Aware. 2007 Jul-Aug;18(4):18-9.
PMID:17682275
Abstract
摘要
相似文献
1
Maraviroc--new HIV drug. Emerging options need to be used wisely.
Posit Aware. 2007 Jul-Aug;18(4):18-9.
2
FDA approval: maraviroc.
AIDS Clin Care. 2007 Sep;19(9):75.
3
FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
AIDS Alert. 2007 Sep;22(9):103.
4
Maraviroc reduces viral load in naive patients at 48 weeks.
AIDS Patient Care STDS. 2007 Sep;21(9):703-4.
5
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Issues Emerg Health Technol. 2007 Dec(110):1-8.
6
Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int. 2008 Jun;17(95):98-101.
7
FDA panel backs HIV drug.
AIDS Read. 2007 Jun;17(6):294.
8
[CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
MMW Fortschr Med. 2011 May 5;153(18):30-1.
9
Maraviroc approved in the European Union.
AIDS Patient Care STDS. 2007 Oct;21(10):779.
10
Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
AIDS Alert. 2009 Jan;24(1):10-2.
引用本文的文献
1
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.
Clin Med Ther. 2009;1:1497-1510. doi: 10.4137/cmt.s2365.
Zotero 插件